24
Sep 2026
Engineered nanoparticles sensitize gliomas to radiotherapy
Gliomas are a major cause of cancer-related deaths in younger adults.
Stay Informed!
24
Sep 2026
GLP-1s linked to nutritional deficiencies in children
Children prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes are at risk for nutritional deficiencies – diagnosed in nearly one in six patients (16.8%) within the first year – according to a new study published in the journal Childhood Obesity.
24
Sep 2026
From lab to living room: Revolutionary Utah bionic arm enters first home trial
At age 16, Alexander “Avi” Davidson fell 35 feet from the top of a telephone pole, an accident that left him paralyzed from the waist down and led to the amputation of his left arm below the elbow.
24
Sep 2026
As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict
A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.
24
Sep 2026
GLP-1 drugs may influence chronic pain through gut-brain and immune pathways
Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.
24
Sep 2026
Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases
A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides approved at the time of writing. It also identifies extrahepatic delivery, safety, target validation, individualized treatment, and data quality as priorities as the field expands into common diseases and explores AI-assisted development.
24
Sep 2026
First foods bring an early functional shift in the infant gut microbiome
Researchers analyzing paired gut microbiome samples from 125 Irish infants found that complementary feeding was associated with early changes in microbial composition and metabolic potential, including an increased capacity for complex carbohydrate metabolism. Breastfeeding duration was more closely associated with microbial community development than the timing of solid-food introduction, while formula-fed infants showed more extensive functional pathway changes after solids were introduced.
24
Sep 2026
Social media influencers shape memorable health messages for young adults
Emily Pfender, assistant professor in the department of communications at the University of Delaware, is a researcher on a new study in Health Communication.
23
Sep 2026
Breath test shows promise for identifying cancerous lung nodules
The human breath could help identify cancerous lung nodules negating the need for invasive testing.
23
Sep 2026
Forge Nano and Nanexa enter joint development agreement to advance manufacturing for ALD-coated PharmaShell® long-acting injectable medicines
Forge Nano, Inc., a leading U.S.-based semiconductor equipment and advanced materials company pioneering Atomic Layer Deposition ("ALD") technology for artificial intelligence ("AI")-era chip manufacturing and defense battery applications, which has signed an agreement to merge with Archimedes Tech SPAC Partners II Co. ("Archimedes II"), today announced a Joint Development Agreement ("JDA") with Nanexa AB to develop scalable pharmaceutical manufacturing capabilities for Nanexa's PharmaShell® drug delivery platform and its portfolio of proprietary and partnered programs.
